Targeting Engineered Nanoparticles for Breast Cancer Therapy

Abstract

Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.

Formulation of Piperine Nanoparticles: In Vitro Breast Cancer Cell Line and In Vivo Evaluation

“…The poor oral bioavailability of PPN corresponds to its high lipophilicity and very limited water solubility (40 μg/mL) [ 13 ]. By considering the above facts, formulation scientists across the world focus on the preparation of novel formulations based on nanotechnology to improve oral bioavailability of lipophilic compounds by increasing aqueous solubility to improve its efficacy against BC [ 14 ].…”

LAPONITE® nanodisk-based platforms for cancer diagnosis and therapy

“…Traditional cancer treatment methods including chemotherapy, radiotherapy and surgery have serious side effects or cannot completely eliminate the tumors. [1][2][3] As a modern technology combining the characteristics of nanomaterials and the therapeutic effects of payload, nanotechnology has been extensively investigated and has been considered to revolutionize the traditional treatment of cancer. [4][5][6] Until now, a few of nanoagents have been approved by the Food and Drug Administration (FDA) for clinical treatment of cancer or are in different stages of clinical studies, such as Doxil ® , Abraxane ® , NanoTherm ® , and Atu027.…”

Enhancing cellular uptake and membrane permeability of gallic acid for breast cancer therapy via folate-tagged PEGylated iron oxide nanoparticles has theronastic agent

“…In addition, the presence of a negative carboxyl group increases the surface charge of nanoparticles and enhances their uptake. However, (Hea-Young Cho 2015; Kumar Ganesan et al 2021) reported that the surface targeting vector (Folate) may precisely target the drug on cancer cells, despite the fact that it retains its ability to bind to receptors after drug conjugation and attaches to the receptors located within caveolae (Mi et al 2011), and it is internalized through the endocytosis pathway and increases the availability of the drug in the cancer cells, which leads to a decrease in cell viability.…”